Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (CLLS)
NASDAQ:CLLS
CLLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.10 - $3.38
Previous CloseN/A
Volume129.50K
Average Volume (3M)98.26K
Market Cap
$118.65M
Enterprise Value$63.37M
Total Cash (Recent Filing)$28.84M
Total Debt (Recent Filing)$5.67M
Price to Earnings (P/E)―
Beta3.61
Next Earnings
May 07, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding72,093,636
10 Day Avg. Volume53,877
30 Day Avg. Volume98,257
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.53
Enterprise Value/Ebitda-4.40
Forecast
1Y Price Target
$5.50Price Target Upside245.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Cellectis SA News
PremiumCompany Announcements
Cellectis Unveils Gene Editing Innovations at ASGCT Meeting
PremiumCompany Announcements
Cellectis S.A. Updates UCART Pipeline with Phase 2 Trial Details
PremiumCompany Announcements
Cellectis Reports 2024 Financial Results and Strategic Advances
PremiumCompany Announcements
Cellectis S.A. Earnings Call Highlights Strategic Growth
---
Bulls Say, Bears Say
Bulls Say
Cash ReservesCellectis had ~$264M in cash which in combination with potential milestone payments is expected to fund the business into 2027.
Financial PerformanceCellectis reported 3Q24 revenue of $18.1M vs. analyst's estimate of $11.2M.
Strategic PartnershipsThe AZN partnership is progressing, initially focused on three programs with an option to expand to ten in total.
Bears Say
DeprioritizationThe development of UCART123 in acute myeloid leukemia (AML) was deprioritized.
Operational CostsCellectis reported a 3Q24 update with opex of $28.8M and a quarter-end cash balance of $264M, up from $165M at YE2023.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
3.39% Mutual Funds
0.63% Other Institutional Investors
95.98% Public Companies and
Individual Investors
CLLS FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was $1.10 and its highest was $3.38 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is $118.65M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is May 07, 2025 which is tomorrow.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on Mar 13, 2025. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.185 by $0.015.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Undervalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.15.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,093,636 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.185. Following the earnings report the stock price went down -3.876%.
Which hedge fund is a major shareholder of Cellectis SA?
Among the largest hedge funds holding Cellectis SA’s share is Bpifrance SA. It holds Cellectis SA’s shares valued at 0.
---
Cellectis SA Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (245.91% Upside)
$5.50 (245.91% Upside)
Blogger Sentiment
Bullish
CLLS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.78%
12-Months-Change
Fundamentals
Return on Equity
-34.08%
Trailing 12-Months
Asset Growth
17.44%
Trailing 12-Months
Company Description
Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
---
CLLS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook for Cellectis, highlighted by strategic collaborations, strong financial positioning, and advancements in clinical trials. Challenges include ongoing arbitration with Servier and patient enrollment progress, but these are outweighed by the company's achievements.Read More>---
CLLS Stock 12 Month Forecast
Average Price Target
$5.50
▲(245.91% Upside)
Technical Analysis
Editas Medicine
―
Nkarta
―
4D Molecular Therapeutics
―
Vor Biopharma
―
Caribou Biosciences
―
---